Volume 3, Issue 1


Cover Image

Cover Figure: Linking of cis-regulatory elements (CREs) to gene expression to identify recurrent mutated noncoding regulatory regions in B-cell lymphoma.
See the article by Cornish et al.

WASHINGTON, January 8,  2019 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.


The CD22-targeting monoclonal antibody inotuzumab ozogamicin was recently approved for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. In a Drug Advances article, Wynne and colleagues describe in detail the development and application of this novel therapeutic.

Hemophagocytic lymphohistiocytosis (HLH) is an often life-threatening disorder of immune dysregulation that results in a constellation of clinical consequences. Preclinical models have implicated interferon-γ in the pathophysiology of HLH. In an Exceptional Case Report presented by Lounder and colleagues, a patient with HLH and a number of severe preexisting conditions including multiple infections was treated with emapalumab, a monoclonal antibody directed against interferon-γ. Hopefully, their results will lead to larger studies of this agent.


While microRNAs have been implicated in many hematological malinancies, their role in normal hematopoiesis is less well defined. Weiss and Ito explore the role of microRNA-22 in megakaryocyte differentiation. Their findings have important biological implications.


Gene editing of hematopoietic stem cells with CRISPR/Cas9-gRNA holds great promise to develop new treatment options for some of the most vexing genetic disorders. However, there are many technical limitations to be overcome. Nasri and colleagues describe a novel method that is validated by editing out a gene involved in DNA repair.


The search for driver mutations is critical to the understanding of many malignancies and has yielded important targets for therapeutic intervention. To date, most of these studies have focused on coding regions of the genome. Cornish and colleagues explore the potential role of noncoding regions of the genome in a large cohort of lymphoma patients.


Featured Visual Abstract

Targeting ubiquitin-activating enzyme induces ER stress–mediated apoptosis in B-cell lymphoma cells

Scott Best, Taylor Hashiguchi, Adam Kittai, Nur Bruss, Cody Paiva, Craig Okada, Tingting Liu, Allison Berger and Alexey V. Danilov







Blood Advances is the open-access journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.